+1 (404) 988-4132
Book a Demo
RF Microneedling
Morpheus8 is an excellent device. For many practices, the obstacle is not the technology, it is the $80,000-plus entry price. The FDA-cleared Newera RF microneedling device delivers the same category of treatment at $41,000, with training, marketing, and a 7-day in-practice trial included.
Both Morpheus8 (by InMode) and Newera are radiofrequency microneedling systems that deliver RF energy through microneedles to remodel collagen in the dermis. They treat the same concerns: fine lines, laxity, texture, and scarring. The practical difference for a practice owner is cost of ownership. Morpheus8 systems are commonly cited in the $80,000-plus range, with training and marketing typically purchased separately. Newera is $41,000 with purchase, subscription, and financing options, and it includes hands-on training through Southern Laser Academy and patient-acquisition marketing support.
Because payback on a capital device is driven mostly by the entry price, a lower-cost system recovers its investment in the fewest treatments. That is the entire case for evaluating Newera as an alternative.
Side by Side
Same category of FDA-cleared RF microneedling. A different cost of ownership.
| Feature | Newera Best Value | Morpheus8 (InMode) $80,000+ tier |
|---|---|---|
| Device price | $41,000 | $80,000+ (approx.) |
| Technology | FDA-cleared 1 MHz bipolar RF microneedling | FDA-cleared fractional RF microneedling |
| Needle depth | 0.5 to 3.5mm, adjustable in 0.1mm steps | Adjustable, varies by handpiece |
| Payment options | Purchase, subscription, or financing | Purchase and limited financing |
| Training | Included via Southern Laser Academy | Typically sold separately |
| Marketing support | Included | Typically not included |
| Try before you buy | 7-day in-practice free trial | Not commonly offered |
Newera and Morpheus8 are RF microneedling systems in the same treatment category. Morpheus8 is a registered product of InMode. Newera is not affiliated with or endorsed by InMode. Competitor details are approximate and provided for general comparison.
What You Get
FDA-cleared 1 MHz bipolar RF, 0.5 to 3.5mm adjustable depth, 25-pin and 49-pin gold-coated tips. Purchase, subscription, and financing structures available.
Hands-on provider training through Southern Laser Academy, an accredited aesthetics training partner, so your team is treating confidently from day one.
Patient-acquisition campaigns to help fill your treatment calendar, bundled in rather than sold as a costly add-on.
Run the device with your own patients for seven days before you commit. See how the trial works.
They are the same category of technology. Morpheus8 is a well-established fractional RF microneedling platform with a strong reputation, and it earned it. Newera is a newer, lower-cost FDA-cleared RF microneedling system aimed at practices that want to add the treatment without an $80,000-plus capital commitment. The honest answer is that the right choice depends on your budget, your patient volume, and how much of the training and marketing you want handled for you. The best way to judge is the 7-day in-practice trial: run it on your own patients, then decide.
How much does Morpheus8 cost vs. Newera?
Morpheus8 systems are commonly cited in the $80,000-plus range depending on configuration; Newera is $41,000 with financing options. Confirm current Morpheus8 pricing with InMode.
Does Newera treat the same concerns as Morpheus8?
Yes. Both are RF microneedling systems used for fine lines, skin laxity, texture, and acne scarring, at provider-selected depths.
What is the catch at a lower price?
There is no catch on quality. Newera keeps the price lower by being a focused, single-device company and by bundling training and marketing rather than selling a large platform of handpieces. The 7-day trial exists so you can verify that for yourself.
See It in Your Practice
Book a 30-minute demo. We will walk the specs, the numbers, and the 7-day in-practice trial, and you can put it side by side with Morpheus8 or any system you are considering.